News Articles for Argent BioPharma

ASX-listed medical cannabis player, MGC Pharmaceuticals has extended its reach to Brazil after signing a three-year exclusive distribution agreement with ONIX Empreendimentos e Participações. Brazil is a key emerging market with specialist market insight provider, Prohibition Partners, estimating that the Brazilian and Latin American medical cannabis sector could be worth up to USD$8.5 billion by 2028.

MGC Pharmaceuticals has received a 50% increase in medical cannabis product orders from Australian distributors Health House International and Cannvalate due to both repeat and new prescriptions. The company also expects to conclude the Phase II clinical trial for its CogniCann medical cannabis treatment for dementia and Alzheimer's patients about 12 months ahead of schedule thanks to the high level of interest.

MGC Pharmaceuticals has received a purchase order of about $700,000 from the first full bulk order of cannabis-based cosmetic raw materials from private Canadian cannabis investment company CannaGlobal. It has also received a $173,000 payment for the delivery of cannabidiol raw material to lifestyle & medical cannabis product manufacturer Mabsut Life under their multi-year supply agreement.

MGC Pharmaceuticals and its research partner RMIT have been awarded a cannabis cultivation research licence from the Australian Office of Drug Control. This allows the partners to advance research on the optimisation of breeding and cultivating processes and the extraction of material to conduct pre-clinical research assessing the efficacy of medical cannabis on prostate, melanoma and other cancer cells.

MGC Pharmaceuticals has made the first shipment of its medical cannabis-derived formulation for the relief of seizures associated with severe epilepsy into the UK. The company's UK distribution partners Grow Biotech and IPS have already received initial prescriptions for the drug. This early interest is encouraging if the company's prediction that the UK medical cannabis market will grow to €8.8bn by 2028.

MGC Pharmaceuticals has signed an exclusive distribution agreement with UK medical cannabis leaders Grow Biotech and IPS, who have an extensive network of 5500 pharmacies across the country. The distributors will ensure that MGC's products are registered with the all relevant authorities and manage the process of importing the products, through to delivering them to patients at home or selected pharmacies.

MGC Pharmaceuticals is expanding its distribution network through agreements with Australian medicinal cannabis distribution and logistics specialists, Health House International and Cannvalate. The non-exclusive agreements cover MGC's IMP products and expand the network of clinics and pharmacies from which Special Access Scheme applications for these products may be derived.

MGC Pharmaceuticals has inked a deal with Chinese e-commerce import platform YuShop Global to sell the Perth-based company's cannabis-based nutraceuticals into the Chinese market. The deal will see MGC Pharma's products sold via YuShop's online platform and network of 1,500 retail channel partners across China, including a luxury spa chain.

MGC Pharmaceuticals has received the green light to import its medicinal cannabis-based epilepsy drug CannEpil into the UK after it was awarded a controlled drug import licence permit. The permit allows the company to immediately expand distribution of CannEpil into the UK medicinal cannabis products market. It is also finalising negotiations with licensed distributors in the UK and Australia.

MGC Pharmaceuticals continues to progress its strategy to commercialise its bio-pharma business with research partner RMIT receiving approval from the Australian Office of Drug Control to possess and handle phytocannabinoids for research purposes. The company has also been awarded a European Union licence to produce non-sterile schedule two medicines in that jurisdiction.

MGC Pharmaceuticals has received independent verification from the University of Ljubljana Biotechnical Faculty and Pharma Lab in Slovenia that its proprietary cannabis strains have industry-leading levels of CBD and THC. The company will now carry out an additional breeding round as part of the genetics registration in the European Union to demonstrate the stability of the strains.

Crusader Resources is pleased to announce the following updates in relation to the Company's funding position.

MGC Pharmaceuticals' botanic division has achieved a significant milestone with its Czech Republic greenhouse delivering 700kg of cannabis biomass in 2018, up 30% from the previous year. The company has also developed a new proprietary genetic strain of cannabis that contains over 35% THC and less than 1% CBD, allowing MGC to obtain more THC per kg of raw material to create cost effective medical cannabis products.

MGC Pharmaceuticals has completed the sale of its cannabis-based cosmetics business, MGC Derma, to CannaGlobal for a 10% stake in the private Canadian cannabis investment company. The company will now focus on its cannabis-based pharmaceutical products and deliver on its seed-to-pharma business model.

MGC Pharmaceuticals has secured approval from Australia's Therapeutic Goods Administration to start the Phase IIB clinical trial of its CogniCann medical cannabis treatment for dementia and Alzheimer's patients. The company's manufacturing facility in Ljubljana, Slovenia, has also secured a permit to extract and develop its own Phytocannabinoid active pharmaceutical ingredients.

MGC Pharmaceuticals has reached a partnership with the Royal Melbourne Institute of Technology and The Hebrew University of Jerusalem to launch an international research hub – Cannahub - for medical cannabis in the first quarter of 2019. Cannahub will initially focus on the use of medicinal cannabis in the treatment of cancer, the effectiveness of traditional and medicinal cannabis combination treatments and drug delivery systems.

MGC Pharmaceuticals has finalised the sale of its cannabis-based cosmetics business, MGC Derma, to CannaGlobal for a 10% stake in the private Canadian cannabis investment company. MGC has also received CAD$500,000 for an initial supply order under an exclusive five-year agreement to supply cannabidiol and cosmetics materials to CannaGlobal for the manufacture of the MGC Derma range of products.

MGC Pharmaceuticals has reached a major milestone after receiving formal authorisation to sell its CannEpil medical cannabis based epilepsy treatment in Australia through specialist prescribers under the Authorised Prescriber Scheme. This signals the start of commercial-scale production of CannEpil at MGC's EU GMP certified facility in Slovenia. CannEpil is expected to generate $1m in annualised revenues from an initial base of about 100 patients.

Lepidico is pleased to advise that the Renounceable Entitlements Offer announced on 3 September 2018 has been well supported by the Company's shareholders and new investors and closed significantly

MGC Pharmaceuticals will focus on its cannabis-based pharmaceutical products after reaching a deal to sell its cannabis cosmetics division, MGC Derma, to Canadian private cannabis investment company CannaGlobal for CAD$12.5m in scrip. CannaGlobal will also commit to an exclusive five-year supply agreement for MGC to supply it with raw materials and proprietary production intellectual for the period.

MGC Pharmaceuticals has signed a key distribution agreement with Maltese based A.M. Mangion that will fast track the distribution of its medical cannabis pharmaceutical products into key target markets in Europe. The company is also weeks away from starting construction of its second medical cannabis production and cultivation facility that will produce GMP-grade pharmaceutical products on a commercial scale.

ASX listed medical marijuana player MGC Pharmaceuticals has received ethics approval to carry out phase two clinical trials into the benefits of its “CogniCann” product for dementia and Alzheimer's patients in early 2019. CogniCann is a GMP certified, pharmaceutical grade, medicinal cannabis product specifically developed for the treatment of dementia symptoms to improve specific cognitive functions.

MGC Pharmaceuticals expects revenues to rise thanks to strong demand for its range of 18 cannabis based skin care products that has prompted UK luxury retailer Harvey Nichols to make them available in two additional stores. The company said the exposure provided by its skin care products may also provide a ready made pathway to market for its fledgling medicinal cannabis business.

MGC Pharmaceuticals' manufacturing facility in Slovenia will now commence production of pharmaceutical grade cannabis derived medicines after receiving a manufacturing licence. The Brett Mitchell chaired company will now begin full scale manufacturing of its epilepsy drug CannEpil for final, independent validation before exportation into Australasia and Europe. CannEpil is already approved for use in Australia.

ASX-listed MGC Pharmaceuticals' bold foray into the global cosmetics market has hit another notable milestone, with luxury UK retailer Harvey Nichols announcing it will stock the company's MGC Derma and Derma Plus skin care lines. MGC says the iconic British retailer will carry the Perth-listed company's premium range of 18 products containing cannabidiol, the non-psychoactive ingredient in cannabis.

ASX-listed MGC Pharmaceuticals' proposed medical marijuana facility in Malta looks set to go ahead after landmark laws legalising medicinal cannabis were passed by the Southern European nation's Parliament. MGC is now on the verge of official approval for its 4,000 square metre facility that it aims to use to launch into the rapidly expanding EU medical marijuana market.

Admedus has appointed Michael Oswell to the newly created role of vice president, development. Based in the US, Mr Oswell has extensive experience in the medical technology industry.

MGC Pharma has stepped up its offering in the multi-million-dollar cannabis-based skincare market, launching its second marijuana-infused dermatological product “CBD Herbal Replenish Cream” aimed at treating inflammatory skin conditions. The release of the company's skin repair product comes after successful clinical tests in Europe. It is the second of three products in MGC's cannabis skincare range.

Thred has announced a capital raising by way of a fully-underwritten, non-renounceable pro-rata entitlement offer at an issue price of $0.004 per new share on the basis of one new share for every t

MGC Pharmaceuticals has raised $5 million in an oversubscribed share placement to construct a 4,000 square metre state-of-the-art medical cannabis production and cultivation facility in Malta. MGC will build the fully-licensed medical cannabis facility after the company was awarded the landmark contract paving the way for it to operate a fully vertically-integrated medical marijuana operation in Europe.

ASX-listed MGC Pharmaceuticals announced today that is has been awarded a contract to build a medical cannabis production facility in Malta, with a $5 million capital raising set to help fund the project.

MGC Pharma has produced its first batch of CannEpil, from its European cannabis factory and the company is now one step away from final certification that will green light the facility for full scale production of medical marijuana products. The drug is set to provide medical relief for epilepsy sufferers with initial sales revenue predictions of AU$1 million per annum for the first year of distribution.

MGC Pharma's new cannabis based diet and vegan vitamin supplement comes in seven different flavours to be sold in both capsule and powder form. The ASX-listed medical marijuana company is tapping into a growing global health supplement market estimated at over US$550 billion. The company said the product meets strict European Union guidelines and will be used to instil “inner health and wellbeing”.

ASX-listed medical cannabis player MGC Pharmaceuticals is set to achieve a major commercial milestone as it edges closer to getting the final green light for its European medical marijuana facility. The company expects to receive official approval for the Slovenian facility this month after being granted an interim licence in January, bringing an 18-month approvals process near to completion.

ASX-listed MGC Pharmaceuticals has been given the green light by Slovenian authorities, who have given the medical marijuana company's European medicinal cannabis production facility a tick of approval. The company has now cleared an important regulatory hurdle for the production of its products in Europe, whilst it also steps up the approvals process for the import of medicinal and beauty brands into Australia.

Revered UK online beauty store business Cult Beauty will distribute MGC Pharmaceuticals medical marijuana skin care products as part of an exclusive sales and marketing deal signed between the two companies. MGC said global distribution channels for its products had substantially expanded following an agreement that will bring many of its products to the fore on a global, web-based catwalk of quality cosmetic brands.

ASX-listed MGC Pharmaceuticals will fast track an Australian operational base to cultivate medicinal marijuana after the federal government announced a plan to legalise exports of cannabis-based medicines. MGC said the regulatory changes, expected to be in place from February, would allow it to establish a pharmaceutical grade medicinal cannabis cultivation strategy to target key export markets.

Medical marijuana company MGC Pharmaceuticals has launched its first “Derma Plus” skin repair product which has been specifically developed to treat mild forms of psoriasis and has hit the shelves for sale through MGC's website and existing eCommerce platforms. The product is available in Australasia, the European Union and the lucrative North American market, where 29 states and counting have legalised marijuana for medicinal use.

MGC Pharma is aiming to hit a series of new highs in 2018 with a number of medicinal and cosmetic cannabis products hitting the shelves in the new year as the company shifts into production phase. The Perth-listed company is moving into the final countdown on the launchpad to the release of its first medical marijuana product to designed treat severe cases of epilepsy.

ASX-listed MGC Pharma is set to rollout a marijuana-derived psoriasis treatment after clinical trials in Europe showed the product, CBD Herbal Repair Cream, was effective at relieving dermatological symptoms such as irritated and inflamed skin. The first product offering from MGC's Derma Plus line, is scheduled for launch in January and will be sold online and through existing channels.